» Articles » PMID: 24967246

Hyaluronan is Not a Ligand but a Regulator of Toll-like Receptor Signaling in Mesangial Cells: Role of Extracellular Matrix in Innate Immunity

Overview
Journal ISRN Nephrol
Specialty Nephrology
Date 2014 Jun 27
PMID 24967246
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Glomerular mesangial cells (MC), like most cell types secrete hyaluronan (HA), which attached to the cell surface via CD44, is the backbone of a hydrophilic gel matrix around these cells. Reduced extracellular matrix thickness and viscosity result from HA cleavage during inflammation. HA fragments were reported to trigger innate immunity via Toll-like receptor-(TLR-) 2 and/or TLR4 in immune cells. We questioned whether HA fragments also regulate the immunostimulatory capacity of smooth muscle cell-like MC. LPS (TLR4-ligand) and PAM3CysSK4 (TLR2-ligand) induced IL-6 secretion in MC; highly purified endotoxin-free HA < 3000 Da up to 50  μ g/mL did not. Bovine-testis-hyaluronidase from was used to digest MC-HA into HA fragments of different size directly in the cell culture. Resultant HA fragments did not activate TLR4-deficient MC, while TLR2-deficient MC responded to LPS-contamination of hyaluronidase, not to produced HA fragments. Hyaluronidase increased the stimulatory effect of TLR2-/-3/-5 ligands on their TLR-receptors in TLR4-deficient MC, excluding any effect by LPS-contamination. Supplemented heparin suppressed every stimulatory effect in a dose-dependent manner. We conclude that the glycosaminoglycan HA creates a pericellular jelly barrier, which covers surface receptors like the TLRs. Barrier-thickness and viscosity balanced by HA-synthesis and degradation and the amount of HA-receptors on the cell surface regulate innate immunity via the accessibility of the receptors.

Citing Articles

Hyaluronic Acid Hampers the Inflammatory Response Elicited by Extracellular Vesicles from Activated Monocytes in Human Chondrocytes.

Carrabs V, Guillen M, Ferrandiz M, Alcaraz M, Ferrini F, Agostini R Pharmaceutics. 2024; 16(11).

PMID: 39598510 PMC: 11597363. DOI: 10.3390/pharmaceutics16111386.


The Challenges of Local Intra-Articular Therapy.

Kirdaite G, Denkovskij J, Mieliauskaite D, Pachaleva J, Bernotiene E Medicina (Kaunas). 2024; 60(11).

PMID: 39597004 PMC: 11596802. DOI: 10.3390/medicina60111819.


Biomimetic Hyaluronan Binding Biomaterials to Capture the Complex Regulation of Hyaluronan in Tissue Development and Function.

Huffer A, Mao M, Ballard K, Ozdemir T Biomimetics (Basel). 2024; 9(8).

PMID: 39194478 PMC: 11351607. DOI: 10.3390/biomimetics9080499.


Activation of sperm Toll-like receptor 2 induces hyperactivation to enhance the penetration to mucus and uterine glands: a trigger for the uterine inflammatory cascade in cattle.

Akthar I, Kim Y, Umehara T, Kanno C, Sasaki M, Marey M Front Immunol. 2024; 14:1319572.

PMID: 38179051 PMC: 10766357. DOI: 10.3389/fimmu.2023.1319572.


Modern Approaches in Wounds Management.

Tatarusanu S, Lupascu F, Profire B, Szilagyi A, Gardikiotis I, Iacob A Polymers (Basel). 2023; 15(17).

PMID: 37688274 PMC: 10489962. DOI: 10.3390/polym15173648.


References
1.
Anders H, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez De Lema G . Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J. 2004; 18(3):534-6. DOI: 10.1096/fj.03-0646fje. View

2.
Pawar R, Patole P, Zecher D, Segerer S, Kretzler M, Schlondorff D . Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol. 2005; 17(1):141-9. DOI: 10.1681/ASN.2005070714. View

3.
Patole P, Pawar R, Lichtnekert J, Lech M, Kulkarni O, Ramanjaneyulu A . Coactivation of Toll-like receptor-3 and -7 in immune complex glomerulonephritis. J Autoimmun. 2007; 29(1):52-9. DOI: 10.1016/j.jaut.2007.04.004. View

4.
Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T . Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med. 2002; 195(1):99-111. PMC: 2196009. DOI: 10.1084/jem.20001858. View

5.
Gannon J . Clinical experiences with intravenous use of sodium hyaluronate in racing greyhounds. Aust Vet J. 1998; 76(7):474-5. DOI: 10.1111/j.1751-0813.1998.tb10185.x. View